115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
一种外用中药通过抑制 NLRP3 炎症小体激活调控角质形成细胞焦亡以缓解银屑病
Authors Wang X, Deng Y, Ren X, Li Y, Liu T, Hu B, Li Y
Received 10 August 2025
Accepted for publication 15 December 2025
Published 15 January 2026 Volume 2026:19 559712
DOI https://doi.org/10.2147/CCID.S559712
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jeffrey Weinberg
Xuewan Wang,1 Yutong Deng,1 Xuewen Ren,2 Yatong Li,1 Tangyunni Liu,1 Bo Hu,1 Yuanwen Li1
1Department of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2Department of Dermatology, Shanxi Provincial Hospital of Traditional Chinese Medicine, Shanxi, People’s Republic of China
Correspondence: Yuanwen Li, Department of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Fangzhuang, Fengtai District, Beijing, 100078, People’s Republic of China, Email b00485@bucm.edu.cn
Purpose: Psoriasis is a chronic inflammatory skin disease involving complex immune dysregulation, where NLRP3 inflammasome-mediated pyroptosis—a pro-inflammatory programmed cell death—has been identified as a key driver of disease pathogenesis. Qingshi anti-itch ointment (QS), a traditional Chinese medicine used for psoriasis, has demonstrated clinical efficacy; however, its specific impact on the NLRP3-pyroptosis pathway remains unclear. This study therefore aims to elucidate the role and underlying mechanisms of QS in regulating NLRP3 inflammasome activation in keratinocytes.
Methods: Psoriasis models were established using both in vivo and in vitro approaches: (1) a mouse model induced by topical application of Imiquimod (IMQ) cream, and (2) a cellular model of keratinocyte pyroptosis stimulated with Lipopolysaccharide (LPS) and Adenosine triphosphate (ATP) in vitro. Therapeutic effects were evaluated through Psoriasis area and severity index (PASI) scoring and Hematoxylin-Eosin staining method (HE). NLRP3 inflammasome-mediated pyroptosis was assessed by IHC, RT-qPCR, and Western blot. Levels of IL-18, IL-1β, IL-17, and IL-22 were measured. Transmission electron microscopy was employed to examine NHEK cellular ultrastructure and pyroptotic status. MCC950, a specific NLRP3 inhibitor, was used to determine whether QS modulates keratinocyte pyroptosis through NLRP3 inflammasome regulation.
Results: QS effectively ameliorated IMQ-induced psoriasiform lesions by suppressing keratinocyte pyroptosis and maintaining cellular integrity. Both in vivo and in vitro experiments demonstrated QS’s ability to inhibit the NLRP3 signaling pathway and selectively regulate key pyroptotic molecules (Caspase-1/GSDMD), thereby reducing proinflammatory cytokine release. Notably, QS combined with MCC950 exhibited significant synergistic effects in suppressing NLRP3 inflammasome activation in both IMQ-induced and LPS/ATP-stimulated models.
Conclusion: QS primarily alleviates psoriasis by modulating keratinocyte pyroptosis through mitochondrial protection, inhibition of GSDMD-mediated membrane perforation, and downregulation of Caspase-1 activity, collectively attenuating inflammatory responses. These findings provide novel mechanistic insights into QS’s anti-psoriatic effects and may facilitate the development of innovative therapeutic strategies for psoriasis.
Keywords: ointment, psoriasis, pyroptosis, NLRP3, inflammasome
1Department of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2Department of Dermatology, Shanxi Provincial Hospital of Traditional Chinese Medicine, Shanxi, People’s Republic of China
Correspondence: Yuanwen Li, Department of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Fangzhuang, Fengtai District, Beijing, 100078, People’s Republic of China, Email b00485@bucm.edu.cn
Purpose: Psoriasis is a chronic inflammatory skin disease involving complex immune dysregulation, where NLRP3 inflammasome-mediated pyroptosis—a pro-inflammatory programmed cell death—has been identified as a key driver of disease pathogenesis. Qingshi anti-itch ointment (QS), a traditional Chinese medicine used for psoriasis, has demonstrated clinical efficacy; however, its specific impact on the NLRP3-pyroptosis pathway remains unclear. This study therefore aims to elucidate the role and underlying mechanisms of QS in regulating NLRP3 inflammasome activation in keratinocytes.
Methods: Psoriasis models were established using both in vivo and in vitro approaches: (1) a mouse model induced by topical application of Imiquimod (IMQ) cream, and (2) a cellular model of keratinocyte pyroptosis stimulated with Lipopolysaccharide (LPS) and Adenosine triphosphate (ATP) in vitro. Therapeutic effects were evaluated through Psoriasis area and severity index (PASI) scoring and Hematoxylin-Eosin staining method (HE). NLRP3 inflammasome-mediated pyroptosis was assessed by IHC, RT-qPCR, and Western blot. Levels of IL-18, IL-1β, IL-17, and IL-22 were measured. Transmission electron microscopy was employed to examine NHEK cellular ultrastructure and pyroptotic status. MCC950, a specific NLRP3 inhibitor, was used to determine whether QS modulates keratinocyte pyroptosis through NLRP3 inflammasome regulation.
Results: QS effectively ameliorated IMQ-induced psoriasiform lesions by suppressing keratinocyte pyroptosis and maintaining cellular integrity. Both in vivo and in vitro experiments demonstrated QS’s ability to inhibit the NLRP3 signaling pathway and selectively regulate key pyroptotic molecules (Caspase-1/GSDMD), thereby reducing proinflammatory cytokine release. Notably, QS combined with MCC950 exhibited significant synergistic effects in suppressing NLRP3 inflammasome activation in both IMQ-induced and LPS/ATP-stimulated models.
Conclusion: QS primarily alleviates psoriasis by modulating keratinocyte pyroptosis through mitochondrial protection, inhibition of GSDMD-mediated membrane perforation, and downregulation of Caspase-1 activity, collectively attenuating inflammatory responses. These findings provide novel mechanistic insights into QS’s anti-psoriatic effects and may facilitate the development of innovative therapeutic strategies for psoriasis.
Keywords: ointment, psoriasis, pyroptosis, NLRP3, inflammasome